Heterogeneity of Diabetes: Beta Cells, Phenotypes and Precision Medicine

Event Details

Celebrating the 100th anniversary of the discovery of insulin in 2021—Diabetes Symposium, Heterogeneity of Diabetes: Beta Cells, Phenotypes and Precision Medicine, June 2–3, 2021. This symposium will capitalize on diabetes research excellence and bring together research leaders to tackle the challenges and opportunities presented by investigation of the heterogeneity of diabetes and to inform on the next steps for research in this area. We look forward to this symposium facilitating engagement and stimulating collaboration among participants through discussions, highlighting critical knowledge gaps and novel approaches in diabetes research.

Registration Deadline

May 21, 2021

Agenda

June 2, 2021

10:00 a.m. – 10:30 a.m. EDT

Opening Remarks
Dr. Francis Collins, Director, National Institutes of Health
Dr. Michael Strong, President, Canadian Institutes of Health Research (CIHR)
Dr. Griffin P. Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Meeting Objectives
Dr. Norman Rosenblum, Scientific Director, Institute of Nutrition, Metabolism and Diabetes (INMD), CIHR
Dr. William Cefalu, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK

Session 1 — Islet Biology In Health And Diabetes

Part 1: Islet Microenvironment
Moderators: Jennifer Estall, McGill University
Alvin Powers, Vanderbilt University

10:30 a.m. – 12:05 p.m. EDT

Islet Microenvironment: Islet Cell Interactions and Heterogeneity
Mark Huising, University of California, Davis

Beta Cell Heterogeneity
Richard Benninger, University of Colorado

Islet Microenvironment: Islet Pericytes and Macrophages
Joana Almaca, University of Miami

Exocrine Pancreas Inflammation and Islet Function
Rebecca Hull-Meichle, University of Washington

Lessons Learned from Human Islet Studies
Patrick MacDonald, University of Alberta

Panel Discussion

12:05 p.m. – 12:20 p.m. EDT

Health Break

Part 2: Islet Engineering
Moderators: Corinne Hoesli, McGill University
Jeffrey Millman, Washington University School of Medicine

12:20 p.m. – 2:00 p.m. EDT

Engineering Islet Endocrine Cells from Stem Cells
Francis Lynn, The University of British Columbia

Engineering the Islet Niche
Juan Melero-Martin, Harvard University

Engineering Islet Organoids for Immune Evasion
Eiji Yoshihara, The Lundquist Institute

Engineering Encapsulation for Replacement Therapy
Cherie Stabler, University of Florida

Engineering Islets on a Chip
Maike Sander, University of California, San Diego

Panel Discussion

2:00 p.m. – 2:15 p.m. EDT

Health Break

Part 3: Beta Cell Stress and Death in Type 1 and Type 2 Diabetes
Moderators: Amelia Linnemann, Indiana University
Jim Johnson, The University of British Columbia

2:15 p.m. – 3:35 p.m. EDT

Beta Cell Stress Pathways in Diabetes
Carmella Evans-Molina, Indiana University

Beta Cell Senescence in Diabetes
Peter Thompson, University of Manitoba

Targeting Beta Cell Unfolded Protein Response in Type 1 Diabetes
Feyza Engin, University of Wisconsin–Madison

Targeting Beta Cell Stress Pathways from Cells to Clinical Trial
Anath Shalev, The University of Alabama

Session 2 — Heterogeneity Of Diabetic Phenotypes Before And After Diagnosis, Impact On Management And Treatment

Part 1: Diversity of Phenotypes and Pathophysiological Endotypes, Impact on Prognosis and Personalized Treatment, Current Research and Knowledge Gaps
Moderators: Meredith Hawkins, Albert Einstein College of Medicine
Christopher Pin, Western University

3:35 p.m. – 5:10 p.m. EDT

Type 1 Diabetes
Maria Redondo, Baylor College of Medicine

Pre-diabetes/Type 2 Diabetes
John Dennis, University of Exeter

T2D in Youth—Phenotypes and Clinical Progression
Kristen Nadeau, University of Colorado

Type 3C Diabetes: Misdiagnosis, Surveillance
Melena Bellin, University of Minnesota

Rare and Atypical Forms of Diabetes Characterization from Monogenic to Polygenic Diabetes
Miriam Udler, Harvard Medical School

Panel Discussion

5:10 p.m. – 5:15 p.m. EDT

Summary
William Cefalu, NIDDK
Norman Rosenblum, INMD, CIHR

June 3, 2021

10:00 a.m. – 10:05 a.m. EDT

Welcome Remarks
William Cefalu, NIDDK
Norman Rosenblum, INMD, CIHR

Part 2: Determinants of Pathophysiological and Clinical Phenotypes, Tools and Strategies for Their Characterization
Moderators: Anna Gloyn, Stanford University
Minna Woo, University of Toronto

10:05 a.m. – 12:05 p.m. EDT

The Interplay Between Environmental and Genetic Factors Determining Diabetes Phenotypes
Satya Dash, University of Toronto

Multiomics/Microbiomics Profiling for Revealing Molecular and Clinical Phenotypes
Wenyu Zhou, Tempus

Is It Possible to Predict Phenotypes? Can Novel Technologies Help?
Michael Snyder, Stanford University

Integration of Electronic Health Records and Big Data as Part of Multidimensional Phenotyping Approach
Gillian Booth, University of Toronto

Panel Discussion

12:05 p.m. – 12:25 p.m. EDT

Health Break

Session 3 — Precision Medicine In Diabetes

Moderators: William Cefalu, NIDDK
Norman Rosenblum, INMD, CIHR

12:25 p.m. – 12:55 p.m. EDT

The Power and Promise of Artificial Intelligence: How It Will Revolutionize Clinical Care
Atul Butte, University of California, San Francisco

12:55 p.m. – 1:25 p.m. EDT

The Future of Precision Medicine and How It Will Transform Diabetes Care
Jose Florez, Harvard Medical School

1:25 p.m. – 2:00 p.m. EDT

Panel Discussion:
Atul Butte, University of California, San Francisco
Jose Florez, Harvard Medical School

2:00 p.m. – 2:40 p.m. EDT

General Symposium Discussion: Considering Our Increased Understanding of the Concept of Heterogeneity, What Does the Future Look Like for Diabetes Research?
Panelists:
Jose Florez, Harvard Medical School
Carmella Evans-Molina, Indiana University
Maike Sander, University of California, San Diego
Miriam Udler, Harvard Medical School

2:40 p.m. – 2:50 p.m. EDT

Wrap-Up/Closing Remarks
William Cefalu, NIDDK
Norman Rosenblum, INMD, CIHR

2:50 p.m. EDT

Adjournment